Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good headline. Stock down 3.5%
We have a fellow traveler on the Sanders bus - LLY, but down only 1.55%.
Size helps to absorb the blow
Once it became clear that AF had sold Bernie a pup the price should have recovered smartly. The fact that it hasn't validates the observation about efficient markets that Dew appends to his posts,
Let's hope Denner is on it.
NVS - beats but hates
Swiss pharmaceuticals company Novartis (NVS) said on Tuesday that growth from new drugs and cost cuts mitigated the impact of patent expiries, as it posted third-quarter earnings that beat forecasts.
Very nicely phrased.
What options are available to Ariad to fight back as fight back they must.
Hard cash flow numbers
do you think a response from ARIA would do anything to the PPS?
A non response wasn't helpful either
What is typical is that electric cars are carbon neutral.
Are you still favorably disposed?
I own a few
There were actually trades at 13.66. After hours trades are often deceptive, tho.
FT
A US drugmaker producing skin creams for common conditions such as acne and eczema has raised the price of two of its treatments to almost $10,000 a tube in the latest instance of “gouging” in the world’s largest healthcare market, according to figures seen by the Financial Times.
Novum Pharma, a Chicago-based group, last week more than doubled the price of the ointments, even after similar increases by other drugmakers prompted outcry and propelled the topic of high healthcare costs into the US presidential campaign.
Agreed, and I own a few, but there are a lot of anti trust related black swans before we get to the promised land.
( Edit - sort of like a discount bond -
Many thanks!
Just the MN's walking it down, nothing to be concerned about (GGG)
JNJ is apparently not participating in the CC.
Hard to put a good spin on that one.
FT
September 4, 2016 11:06 am
Emerging markets on track to set sovereign debt record
Developing economies are on course to raise a record sum on global debt markets this year, as ultra-low rates in the developed world cheapen borrowing costs for countries from Asia to South America.
After a slow start, governments in countries including Mexico, Qatar and Argentina have issued bonds worth $90bn in 2016. By the end of the year, credit strategists at JPMorgan expect sales of debt by emerging markets in “hard” currencies such as dollars and euros to reach more than $125bn — boosted by Saudi Arabia’s first appearance on global bond markets.
A punishingly low yield environment for money managers has sparked a jump in demand for emerging market fixed debt in the past few months, as lack of inflation keeps interest rates in big economies on hold and prompts additional monetary easing from the European Central Bank, the Bank of Japan and the Bank of England. >snip<
Guardian
Psychiatric drugs do more harm than good and the use of most antidepressants and dementia drugs could be virtually stopped without causing harm, an expert on clinical trials argues in a leading medical journal.
Given their lack of benefit, I estimate we could stop almost all psychotropic drugs without causing harm
Peter Gøtzsche
The views expressed in a British Medical Journal debate by Peter Gøtzsche, professor and director of the Nordic Cochrane Centre in Denmark, are strongly opposed by many experts in mental health. However, others say the debate around the use of psychiatric drugs is important and acknowledge that there has been overuse of antipsychotics to quieten aggressive patients with dementia.
Gøtzsche says more than half a million people over the age of 65 die as a result of the use of psychiatric drugs every year in the western world. “Their benefits would need to be colossal to justify this, but they are minimal,” he writes.
He claims that trials carried out with funding from drug companies into the efficacy of psychiatric drugs have almost all been biased, because the patients involved have usually been on other medication first. They stop their drugs and often experience a withdrawal phase prior to starting the trial drug, which then appears to have a big benefit. He also claims that deaths from suicide in clinical trials are under-reported.
The stories you need to read, in one handy email
Read more
In trials of the modern antidepressants fluoxetine and venlafaxine, says Gøtzsche, it takes only a few extra days for depression in the placebo group – given dummy pills – to lift as much as in the group given the drugs. He argues that there is spontaneous remission of the disease over time.
Results from trials of schizophrenia drugs are also disappointing, he argues, and those for ADHD (attention deficit hyperactive disorder) are uncertain. “The short-term relief seems to be replaced by long-term harms. Animal studies strongly suggest that these drugs can produce brain damage, which is probably the case for all psychotropic drugs,” he writes.
“Given their lack of benefit, I estimate we could stop almost all psychotropic drugs without causing harm – by dropping all antidepressants, ADHD drugs and dementia drugs … and using only a fraction of the antipsychotics and benzodiazepines we currently use.
“This would lead to healthier and more long-lived populations. Because psychotropic drugs are immensely harmful when used long-term, they should almost exclusively be used in acute situations and always with a firm plan for tapering off, which can be difficult for many patients.”snip
IV as a psychological indicator still holds some sway, surely
The Telegraph is giddy (not necessarily a reco)
Scientists said they were amazed to find that patients treated with the highest dose of the antibody drug aducanumab experienced an almost complete clearance of the amyloid plaques that prevent brain cells communicating, leading to irreversible memory loss and cognitive decline.
"These findings could be a 'game changer' if the effects on memory decline can be confirmed in more extensive follow-on studies"David Allsop, Professor of Neuroscience, University of Lancaster
Crucially they also found that after six months of the treatment, patients stopped deteriorating compared with those taking a placebo, suggesting that their dementia had been halted.
Nature
Alzheimer’s disease (AD) is characterized by deposition of amyloid-ß (Aß) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aß to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aß. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aß, and reduce soluble and insoluble Aß in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aß in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating—Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
Both of my surmises were wrong,lol!
Thank you.
Small position in TRIL, may have missed information I shouldn't have.
Was the recent activity FDA filing related, or are there buy out rumors?
I pared my position a month or so ago. Beat you to it.
snipped from the FT
The string of food safety problems at Chipotle Mexican Grill last year, including outbreaks of e-coli and salmonella, wiped 40 per cent off the company’s shares. A year later, customer numbers are still down sharply.
Not by coincidence, the burrito chain has been the focus of one of the biggest corporate governance fights of 2016. Some shareholders blame a stale, insular board of directors for failing to move fast enough or aggressively enough to deal with the crisis.
The company is emblematic, campaigners say, of how too many of America’s boardrooms are failing to protect investors’ interests. A Financial Times analysis of data from the shareholder advisory group ISS Analytics shows US boards are “maler, staler and frailer” than their European counterparts, having directors who are older on average, stay in post longer and are less likely to be women.
There is a straight line between the ensconced position of many board members — the average tenure of Chipotle’s current directors is 13 years, five years more than the US average — and a “slow, superficial and unconvincing” response to the safety issues, according to CtW Investment Group, which represents union pension funds and wrote a thunderous public letter to fellow shareholders.
“Chipotle is in need of genuinely independent oversight now more than ever,” CtW wrote, complaining that one of the longest-tenured directors had been put in charge of overseeing food safety issues for the audit committee. “Its growth has long since outsized its governance arrangements.”<snip
We should have learned by now that Denner is close lipped - we'll know what he wants us to know when he decides. Until then he'll hold his tongue.
From both ends.
Dew, can you figure out the pricing in ACAD?
Given the pricing of the offering, I thought 31.55 would be a steal.
Some steal
whether the future was in another Biotech company (that he owned as well) or Ariad....
Was the "other" company VVUS by any chance?
You were right. I got suckered by the potential explosive payoff.
I should leave such plays to the SI contest.
ARRY
Selumetinib bombed
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients
BOULDER, Colo., Aug. 9, 2016 /PRNewswire/ -- AstraZeneca (LON/STO/NYSE: AZN) today announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC). Array BioPharma (NASDAQ: ARRY) was informed of these results on Monday, August 8, 2016.
Array BioPharma. (PRNewsFoto/Array BioPharma Inc.)
The results showed that the trial did not meet its primary endpoint of progression-free survival (PFS), and selumetinib did not have a significant effect on overall survival (OS). The adverse event profiles for selumetinib and docetaxel were consistent with those seen previously.
- See more at: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=RssLanding&cat=news&id=2194007#sthash.cj8wBa8U.dpuf
Thanks. Seems like they remain in a favorable place
AGN
Any views?
ARRY?
any body know why the move?
There are 30M+ shorts who are temporarily in the way
How are the shorts in the way? They're a source of future demand. Wish there were more to create a tsunami that would clear everything in its path when they have to cover.
The tailwind has moved upstream but it still exists, even if the low hanging fruit has been picked
Not always easy to tease out the investment suggestion tho. Still I'd keep it for the occasional bingo.
Implying that the tailwind has petered out or has been affected by too many crosswinds?
I've never had a glimmer of thought of suicide, but this would do it
are dragged off to dialysis twice a week.